Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjöström J, Kjaer M; Scandinavian Breast Group Trial (SBG9403. Ejlertsen B, et al. Among authors: sjostrom j. J Clin Oncol. 2004 Jun 15;22(12):2313-20. doi: 10.1200/JCO.2004.11.503. J Clin Oncol. 2004. PMID: 15197192 Clinical Trial.
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H, Bergh J. Sjöström J, et al. Eur J Cancer. 1999 Aug;35(8):1194-201. doi: 10.1016/s0959-8049(99)00122-7. Eur J Cancer. 1999. PMID: 10615229 Clinical Trial.
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
Hakamies-Blomqvist L, Luoma M, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Ostenstad B, Mjaaland I, Ottosson-Lönn S, Bergh J, Malmström P, Blomqvist C. Hakamies-Blomqvist L, et al. Among authors: sjostrom j. Eur J Cancer. 2000 Jul;36(11):1411-7. doi: 10.1016/s0959-8049(00)00126-x. Eur J Cancer. 2000. PMID: 10899655 Clinical Trial.
Timing of quality of life (QoL) assessments as a source of error in oncological trials.
Hakamies-Blomqvist L, Luoma ML, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Østenstad B, Mjaaland I, Ottosson S, Bergh J, Malmström PO, Blomqvist C. Hakamies-Blomqvist L, et al. Among authors: sjostrom j. J Adv Nurs. 2001 Sep;35(5):709-16. doi: 10.1046/j.1365-2648.2001.01903.x. J Adv Nurs. 2001. PMID: 11529973
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.
Sjöström J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmström P, Østenstad B, Wist E, Valvere V, Bergh J, Skiöld-Petterson D, Saksela E, Blomqvist C. Sjöström J, et al. Eur J Cancer. 2002 Mar;38(4):535-42. doi: 10.1016/s0959-8049(01)00403-8. Eur J Cancer. 2002. PMID: 11872346 Clinical Trial.
70 results